Keystone Labs Keeps OTC Drugs In Plans After Court Orders Manufacturing Halt
Executive Summary
Keystone Labs agrees to cease manufacturing OTC drugs after repeat GMP violations following a 2013 FDA warning letter, including failure to investigate sources of contamination. Firm says it informed FDA it would outsource OTC product manufacturing and continue making hair and skin care cosmetic formulas.
You may also be interested in...
FDA Consumer Health Product Recalls For May 4-25, 2016
Recalls reported by FDA for OTC drugs, nutritionals and personal care products.
In Brief
New studies from Chanel researchers and Gettysburg College support makeup’s anti-aging effect. More news in brief.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.